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Purpose: This study was undertaken to investigate the
outcomes associated with docetaxel treatment of Korean
patients with hormone-refractory prostate cancer (HRPC) and
to compare its clinical efficacies in 1st and 2nd-line settings.
Patients and Methods: This study was retrospectively per-
formed and included 47 patients with HRPC. The 1st-line
group consisted of 19 patients who had not undergone prior
chemotherapy, and the 2nd-line group consisted of 28 patients
who underwent prior chemotherapy. All patients were treated
with 75 mg/m
2 IV docetaxel every 3 weeks and 5 mg of
prednisone twice daily with a continuous androgen blockade.
Results: Of 47 study subjects, 14 patients (29.8%) had 50%
PSA decline from baseline. PSA response was more common
in the 1st-line group, but this was not statistically different
(42.1% vs. 21.4%, p = 0.114). After a median follow up of 11
months (range, 6 - 24 months), the 1st-line group showed a
longer time to PSA progression (4 vs. 2 months, p = 0.015)
and survival (17 vs. 10 months, p = 0.037) than the 2nd-line
group. In terms of toxicities, no difference was apparent
between the 2 groups. Conclusion: In a 1st-line setting,
docetaxel is an effective and tolerable agent for Korean HRPC
patients, and that its efficacy is limited, although 2nd-line
docetaxel is tolerable.
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INTRODUCTION
Prostate cancer is the second most common
cause of cancer-related deaths in men in the
United States and its occurrence is rapidly
increasing in Korea.
1,2 Early-stage prostate can-
cer can be cured by radical surgery or radiation
therapy, but many newly diagnosed patients
have advanced stage prostate cancer.
3 In 1941,
Huggins and Hodges first reported the efficacy
of androgen deprivation therapy in advanced
prostate cancer.
4 Subsequently, androgen depri-
vation treatment became the most effective
systemic approach for patients with metastatic
disease. Although 80 - 90% of patients initially
respond favorably to this treatment, all patients,
however, eventually develop "hormone-refrac-
tory prostate cancer (HRPC)", which is unres-
ponsive to androgen deprivation.
5,6 Unfortuna-
tely, treatment for HRPC is limited and some
forms of chemotherapy have been shown to
provide a palliative effect, but no survival
gain.
7-10
Two recent phase III trials showed that
docetaxel plus estramustine or prednisone im-
proved overall survival versus mitoxantrone
plus prednisone.
7,8 Subsequently, docetaxel was
strongly advocated as a standard treatment for
metastatic HRPC. Currently, docetaxel is ad-
ministrated to HRPC patients in Korea, but no
report on clinical outcomes of docetaxel
therapy in our country has been published.
We, therefore, undertook this study to
investigate the outcomes of docetaxel for the
treatment of HRPC in Korean patients, and to
compare its clinical efficacies in 1st and 2nd-
line settings.
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PATIENTS AND METHODS
Patients
From January 2005 through September 2007, 47
patients who had received docetaxel chemo-
therapy for the treatment of HRPC were enrolled
in this study. Patient records were retrospectively
reviewed to determine the base-line characteristics
of patients and the clinical efficacy and tolerability
of docetaxel. All patients had histologically con-
firmed adenocarcinoma of the prostate, evidence
of metastasis, and progressive disease despite
complete androgen blockade therapy, anti-andro-
gen withdrawal, and an Eastern Cooperative
Oncology Group (ECOG)-Performance Status of 0
to 2. Progressive disease was defined by an
increase in PSA levels as determined by 2 con-
secutive measurements at least 2 weeks apart, an
increase in the size of a measurable lesion by
computed tomography (CT) or any newly
developed bony metastasis with hot uptake by
bone scan. Bone scan was considered stable if
there were no new lesions in 2 scans at least two
months apart. Androgen suppression was
confirmed by serum testosterone measurements.
Informed consent was obtained prior to each
therapy. To investigate differences according to
prior chemotherapy, patients were classified into
2 groups; the 1st-line group consisted of patients
who had undergone no prior chemotherapy,
whilst the 2nd-line group had undergone prior
chemotherapy. The 1st-line therapy for each
HRPC patient in this study was determined at
physician’s discretion, based on cancer-related
symptoms, rising PSA, extent of metastasis and
performance status.
Treatment and follow-up
Pretreatment evaluation included a complete
medical history-taking, a physical examination,
complete blood cell count, serum chemistry
profile, serum PSA, bone scan, CT of the pelvis
and abdomen, and chest X-ray. Patients were
treated with 75 mg/m
2 IV docetaxel every 3 weeks
and 5 mg of prednisone twice daily, following
premedication with 8 mg of dexamethasone.
Patients who had not undergone orchiectomy
were required to continue androgen blockade
with a luteinizing hormone-releasing hormone
(LHRH) analogue. Patients underwent physical
examination, CBC, LFT and renal function test
before docetaxel administration, and 7 days after
each docetaxel administration. Patients were
followed up by using 3 weekly PSA determina-
tions before docetaxel administration. In patients
with measurable disease, tumor assessments were
performed every 3 cycles until progression or
sooner, if possible. Visual analogue pain scale
(VAS) was also routinely applied during each
docetaxel cycle. Chemotherapy was continued
until disease progression or unacceptable adverse
events occurred. All patients received this
docetaxel treatment as an in-patient each cycle.
Endpoint evaluations
All patients were evaluated for PSA response,
objective measurable disease response, subjective
pain response, time to PSA progression, and
survival. In particular, we investigated differences
between the clinical outcomes of the 1st and
2nd-line groups.
PSA response
The criteria used for determining response were
based on the guidelines of the PSA working
group.
9 A PSA decline of 50%, confirmed by a
second value at least 3 weeks later, was con-
sidered as a PSA response. Additionally, stable
disease was defined as a PSA decrease, which did
not satisfy PSA response criteria. Progression was
defined as the increase of PSA on the contrary.
Baseline PSA was defined as the PSA value
obtained within a 2-week period prior to starting
the study medication.
Time to PSA progression and overall survival
The start of the time to PSA progression was
the day when treatment was initiated. If at least
50% decline of PSA has been achieved, end date
was the time when PSA has increased of 50%
above the nadir at a minimum of 5 ng/mL. For
patients that did not experience a PSA decrease of
this magnitude (or no decrease), the end point for
progression was calculated as the time of 25%
increase in baseline or nadir PSA. All end datesDocetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer
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required a confirmatory PSA test. Overall survival
was defined as the time between first docetaxel
administration and death.
Objective measurable disease and subjective pain
response
Objective response was documented using
evaluable radiographs according to the Response
Evaluation Criteria of Solid Tumors (RECIST).
10
For bone metastasis, stable disease was defined if
there were no new lesions in two bone scans
taken at least 2 months apart. Subjective pain
responses were measured using the VAS. Pain
relief was defined as a decline of 2 points in
VAS scores of at least 1-month duration versus
baseline scores.
Toxicity
The National Cancer Institute Common Toxicity
Criteria version 2.0 was used to evaluate patients
for toxicity during each cycle. If Grade 3 or 4
hematologic or non-hematologic toxicities were
observed during any cycle, the docetaxel dose was
then temporarily deescalated to 75% of the
original dose for following treatment cycles until
recovery, and a reescalated dose was then
recommended. If the same toxicity reappeared at
any time, the reduced dose was maintained
throughout.
Statistical analysis
The major statistical endpoints of this study
consisted of PSA response, time to PSA progres-
sion, and overall survival. We also investigated
differences between these endpoints in 1st and
2nd-line groups. Time to PSA progression and
survival curves were produced using the Kaplan-
Meier method and differences between the 1st
and 2nd-line groups were compared using the
log-rank test. The T test (or Mann-Whitney test for
non-parametric variables) was used for continu-
ous variables, and the Chi-square (or Fisher's
exact test for non-parametric variables) was used
for categorical variables. P values of < 0.05 (2-
sided) were considered statistically significant,
and confidence intervals were set at the 95% level.
All analyses were performed using the Statistical
Package for the Social Sciences for Windows Ver.
11 (SPSS Inc, Chicago, IL, USA).
RESULTS
Patient characteristics
The baseline characteristics of the 47 patients
are listed in Table 1. The median pretreatment
PSA level was 180 ng/mL (range, 12 - 8788 ng/
mL), and there was no significant difference
between the baseline PSA levels of the 1st and
2nd-line groups. In terms of visceral metastases,
2 patients had lung lesions, 1 patient had a liver
lesion and another patient had a brain lesion.
Most patients had bone or LN metastasis. In terms
of the subgroup analysis, 19 patients received
docetaxel as the 1st-line chemotherapy, and 28 as
the 2nd-line chemotherapy. Of these 28 patients,
21 had previously received mitoxantrone and 7
had received 280 mg estramustine. In addition, 8
of the 28 2nd-line chemotherapy patients (28.6%)
had previously received palliative radiation.
However, none of the 2nd-line chemotherapy
patients had received any cytotoxic drug or
radiotherapy during the month preceding the
study period.
Response
Serum PSA
Of the 47 study subjects, 14 (29.8%) experienced
a PSA decline of 50% from baseline that had
lasted for 4 weeks, which constituted PSA
response. PSA response was more frequently
demonstrated in the 1st line group (42.1% vs.
21.4%), but this was not significant (p = 0.128).
Stable disease and progression disease were
presented by 18 (38.3%) and 15 (31.9%) of the
study subjects, respectively (Table 2).
Responses of measurable lesions (Table 2)
Twenty-nine study subjects had measurable
metastasis, revealed by radiographic examina-
tions, which included CT and MRI; i.e., lung in 2,
liver in 1, brain in 1, and LN plus bone in 25
patients. Of evaluable these 29 patients, one
patient with brain lesions achieved complete
response (CR) and 2 patients with lung and 1Table 2. Responses of Serum PSA and Measurable Disease to Docetaxel
Response of serum PSA 1st-line (n = 19) 2nd-line (n = 28) Total (n = 47) p value
Partial response (decline 50%) 8 (42.1%) 6 (21.4%) 14 (29.8%) 0.128
Stable disease (0 < decline < 50%) 8 (42.1%) 10 (35.7%) 18 (38.3%) 0.658
Progression disease 3 (15.8%) 12 (42.9%) 15 (31.9%) 0.063
Response of measurable disease 1st-line (n = 13) 2nd-line (n = 16) Total (n = 29) p value
Complete response 1 (7.7%) 0 (0%) 1 (3.4%) 0.448
Partial response 2 (15.4%) 1 (6.3%) 3 (10.3%) 0.573
Stable disease 7 (53.8%) 7 (43.8%) 14 (48.3%) 0.588
Progression disease 3 (23.1%) 8 (50.0%) 11 (37.9%) 0.249
PSA, prostate-specific antigen.
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Table 1. Patient Characteristics
Variables
1st-line group
(n = 19)
2nd-line group
(n = 28)
Total
(n = 47)
p value
Median age (range) 64 (52 - 77) 69 (55 - 84) 68 (52 - 84) 0.076
Median baseline PSA (range) 161 ng/mL
(12 - 8788)
195 ng/mL
(24 - 2465)
180 ng/mL
(12 - 8788)
0.492
PSA doubling time 0.304
3 months 14 (73.7) 24 (85.7) 38 (80.9)
> 3 months 5 (26.3) 4 (14.3) 9 (19.1)
Median ECOG-PS (range) 0 (0-1) 1 (0-1) 0 (0-1) 0.137
No. of course per patient 6 (3-19) 6 (3-9) 6 (3-19) 0.126
Sites of metastasis (%) 0.555
Bone only 15 (78.9) 17 (60.7) 32 (68.1)
Bone and visceral 1 (5.3) 2 (7.1) 3 (6.4)
Bone and LN 3 (15.8) 8 (28.6) 11 (23.4)
Bone, LN, and visceral 0 (0.0) 1 (3.6) 1 (2.1)
Prior chemotherapy (%)
None 19 (100) 0 (0) 19 (40.4)
Mitoxantrone 0 (0) 21 (75.0) 21 (44.7)
Estramustine 0 (0) 7 (25.0) 7 (14.9)
Prior palliative RT (%) 0.551
None 12 (63.2) 20 (71.4) 32 (68.1)
EBRT 7 (36.8) 8 (28.6) 15 (31.9)
PSA, prostate-specific antigen; ECOG-PS, Eastern Cooperative Oncology Group-Performance Status; LN, lymph node; RT,
radiation therapy; EBRT, external beam radiation therapy.Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer
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patient with LN lesions achieved partial response
(PR). Objective response including CR and PR
appeared in 3 (23.1%) in the 1st-line and only one
patient (6.3%) in the 2nd-line, which did not show
any significant difference (p = 0.299).
Subjective pain responses
Of the 30 evaluable study subjects, 16 (53.3%)
symptomatic patients showed an improvement in
VAS pain scores of 2 points versus baseline pain
scores, over a period of at least 2 months. Whereas
8 of 16 patients with symptomatic improvement
had an accompanying decrease in PSA, the other
8 demonstrated only pain improvement without a
PSA decline or objective response. No difference
in subjective pain response was observed between
the 2 groups (data not shown).
Time to PSA progression and survival
Given a median follow-up of 11 months (range,
6 - 24 months) for all study subjects, 42 patients
ultimately experienced PSA progression despite
therapy. Moreover, no difference in mean follow-
up duration was observed between the two
groups (11 months in the 1st-line group vs. 9
months in the 2nd-line group, p = 0.798). Only 1
patient showed a continuously decreasing serum
PSA level over 9 months after docetaxel admini-
stration. He received docetaxel in a 1st-line setting
and had bone metastasis; his baseline PSA level
was 98 ng/mL. Median time to progression for
study subjects was 3.0 months (range, 1 - 14
months). At the time of analysis, 23 were
remained alive and 24 patients died of prostate
cancer. Median survival was 12.0 months (range,
3 - 24 months). The 1st-line group showed the
longer median time to PSA progression (4.0 vs. 2.0
months, p = 0.015) and survival (17 months vs 10
months, p = 0.037) than the 2nd-line group. Time
to PSA progression and the overall survival curve
are presented in Figs. 1 and 2, respectively.
Toxicity
Toxicity findings are summarized in Table 3. In
terms of hematologic toxicities, neutropenia and
leukopenia were common, and were found in 27
(57.4%) and 28 (59.6%), respectively, but no
difference was apparent between the 2 groups
(57.9% vs 57.1% for leukopenia, p = 0.959; and
68.4% vs 53.6% for neutropenia, p = 0.309). Grade
3 - 4 neutropenia occurred in 19 patients (40.4%),
which showed no difference between the two
groups (47.4% vs 35.7%, p = 0.424). Dose reduction
was required temporarily in 19 patients (40.4%)
due to hematologic toxicities, and most recovered
within 2 weeks. Of these, 12 patients required
granulocyte-colony stimulating factor (GCSF) and
5 patients were maintained at 75% of the original
dose because of repetitive hematologic toxicities.
Grade 3 neutropenic fever occurred in 2 patients
Fig. 1. Times to PSA progression in the 1st and 2nd-line
groups (p = 0.015). PSA, prostate-specific antigen.
Fig. 2. Overall survivals in the 1st and 2nd-line groups (p
= 0.037).
1st-line group
2nd-line group
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who recovered with supportive care that included
hydration and antibiotics. In terms of non-hema-
tologic toxicities, grade 1 to 2 sensory neuro-
pathies, such as paresthesia of the extremities,
were most frequently found in 13 patients (27.7%).
However, no patient developed a grade 3 - 4 non-
hematologic toxicity, and all patients who
developed a non-hematologic toxicity recovered
with conservative treatment.
DISCUSSION
Docetaxel is considered as a promising agent
because of its excellent experimental results in
vitro and its theoretical background. The studies
to evaluate the ability of docetaxel to stabilize
tubulin, found that it had a significant anti-tumor
effect in androgen-dependent and androgen-
independent prostate cancer cell lines.
11,12 In
addition, docetaxel caused apoptosis by inducing
phosphorylation of bcl-2, which found to be
overexpressed in androgen-resistant prostate
cancer.
13 Thus, these in vitro results encouraged
the clinical use of docetaxel in HRPC patients. In
2004, 2 randomized trials, TAX 327 and the
Southwest Oncology Group (SWOG) 99 - 16 trial,
showed for the first time a survival benefit for
docetaxel in men with metastatic HRPC.
7,8
Specifically, median overall survival in the TAX
327 trial was improved by 2.4 months in the
docetaxel (administered every 3 weeks) arm
versus the mitoxantrone arm (also administered
every 3 weeks) (18.9 vs. 16.5 months, resp., p =
0.009), which led the US FDA in 2005 to approve
docetaxel as chemotherapeutic agent in HRPC
patients.
7
In the present study, the PSA response rate for
all study subjects was 21%, which was lower than
those found in two landmark studies (45% in TAX
327 and 50% in SWOG 99 - 16), which may have
been due to different patient characteristics. Our
patients had a median baseline PSA level of ca.
180ng/mL, which was substantially higher than
those of previous studies; i.e., 114 ng/mL in TAX
327 and 90 ng/mL in SWOG 99 - 16. Moreover,
our study included more patients who had
received prior chemotherapy than previous
Table 3. Toxicity
1st-line group (n = 19) 2nd-line group (n = 28) Total (n = 47) p value
Hematologic
Leukopenia 11 (57.9%) 16 (57.1%) 27 (57.4%) 0.959
Grade 1 - 2 7 (36.8%) 10 (35.7%) 17 (36.2%) 0.937
Grade 3 - 4 5 (26.3%) 6 (21.4%) 11 (23.4%) 0.698
Neutropenia 13 (68.4%) 16 (57.1%) 29 (61.7%) 0.435
Grade 1 - 2 4 (21.1%) 6 (21.4%) 10 (21.3%) 1.000
Grade 3 - 4 9 (47.4%) 10 (35.7%) 19 (40.4%) 0.424
Neutropenic fever 0 (0%) 1 (3.6%) 1 (2.1%) 0.778
Thrombocytopenia 2 (10.5%) 4 (14.3%) 6 (12.8%) 0.705
Non-hematologic
Paresthesia of extremities 5 (26.3%) 8 (28.6%) 13 (27.7%) 0.865
Oral mucositis 3 (15.8%) 5 (17.9%) 8 (17.0%) 0.853
Nausea and vomiting 2 (10.5%) 3 (10.7%) 5 (10.6%) 1.000
Diarrhea 1 (5.3%) 3 (10.7%) 4 (8.5%) 0.638
No patient developed a grade 3 - 4 non-hematologic toxicity.Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer
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studies. When subgroup analysis was performed
in the 1st-line group, PSA response rate increased
to 42.1%. Moreover, our median survival was 12
months (95% confidence interval, 9.75 - 16.25
months), which was somewhat lower than those
of the 2 above-mentioned landmark trials. Because
our study was limited by the small number
patients enrolled and its retrospective nature, we
were unable to identify the cause of poor response
rate to docetaxel chemotherapy by comparing to
previous trials. However, in these previous trials,
patients received docetaxel as 1st-line chemo-
therapy, whereas most of our patients were
heavily pretreated as mentioned above; i.e., 31.9%
had received palliative radiation and 59.6% prior
chemotherapy, such as, mitoxantrone or estramus-
tine. Therefore, the start of docetaxel treatment
was usually late in the present study, and these
patient characteristics could well explain the
differences between these previous studies and
present study in terms of clinical outcomes, such
as PSA response, time to PSA progression, and
overall survival.
A few studies have examined outcomes of
docetaxel chemotherapy in Asian countries, espe-
cially as a 2nd-line treatment.
14,15 Thus, it is worth
noting that the present study is the first to be
conducted on the efficacy of docetaxel in Korean
patients, and that it included patients with
progressive disease despite prior chemotherapy;
i.e., mitoxantrone-resistant and estramustine-
resistant cases. A small number of studies
conducted in the West have evaluated PSA
response rates after cross over from mitoxantrone
to docetaxel and vice versa. However, reported
PSA response rates, palliation efficacies, and
tolerabilities were variable and dependent on
disease extent, treatment duration, and patient
performance status.
16-18
In the present study, docetaxel was generally
tolerable, and no patient was lost due to toxicity.
Leukopenia, neutropenia, and paresthesia of the
extremities were the predominant side effects, and
the hematologic toxicity was comparable to that
reported previously.
7,8 Furthermore, patients well
tolerated 2nd-line docetaxel, and its toxicities
were comparable to those of 1st-line treatment.
No standard chemotherapy has yet been
established for Korean HRPC patients. The
Korean FDA also approved docetaxel for the
treatment of HRPC in 2005, and therefore,
docetaxel is actively being administrated to many
patients throughout Korea. However, no clinical
report has yet been published on the clinical
efficacy of docetaxel chemotherapy in Korean
HRPC patients. Two docetaxel regimens could be
suggested; i.e., docetaxel plus prednisone or
estramustine. In the SWOG 99 - 16 trial, median
overall survival was better for docetaxel plus
estramustine than mitoxantrone plus prednisone.
However, docetaxel plus estramustine was
associated with more frequent incidents of
cardiovascular and thromboembolic toxicities.8 In
view of these side effects together with the fact
that the estramustine combination has no survival
benefit, we would recommend 75 mg/m
2
docetaxel (3 weekly) plus prednisone, because of
its effectiveness and acceptable toxicity in Korean
HRPC patients.
The optimal timing of docetaxel chemotherapy
is an issue that should be considered. However,
no prospective clinical trial has indicated whether
early treatment is more effective than delayed
treatment. Some experts in the field recommended
that mitoxantrone plus prednisone with palliative
radiation therapy should be offered to the patients
with a slow PSA doubling time and asymptomatic
disease should be observed, that patients with a
slow PSA doubling time and symptomatic bone-
only disease, and that patients with a rapid PSA
doubling time and/or symptomatic disease and/
or visceral metastases should be treated with a
docetaxel-based chemotherapy.
19-21 Recently, doce-
taxel has strongly been recommended as a 1st-line
treatment in our institution for HRPC patients
with a rapidly increasing PSA or symptomatic
metastasis.
Although our 2 study groups were comparable
in terms of patient characteristics (including
baseline PSA), our study is intrinsically limited by
its retrospective nature. Furthermore, the fact that
the 1st-line therapy for HRPC patients was
determined at physician's discretion is an another
limitation. Docetaxel was administrated to
patients with symptomatic metastatic HRPC,
which meant that time to docetaxel treatment was
greater than in previous studies. Therefore, the
selection bias could exist, thus making us toJae Young Joung, et al.
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perform cross-study comparisons.
In conclusion, docetaxel in a 1st-line setting was
found to be effective and tolerable in Korean
HRPC patients. 2nd-line docetaxel was also found
to have tolerable toxicity, but its efficacy was
limited. Nevertheless, additional multi-institu-
tional studies are required to obtain a meaningful
result concerning the survival benefits of
docetaxel in Korean HPRC patients.
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